

Figure 1:




Figure 2:

Heatmap	Urelumab	Utomilumab	PRO885	PRO951
PRO885	29%	35%	0%	48%
PRO951	34%	0%	22%	0%

Bindinglevel normalized to theoretical Rmax [%]


Figure 3:


Figure 4:

Figure 5:




Figure 6:




Figure 7:




Figure 8:




Figure 9:




Figure 10:




Figure 11:




Figure 12:




Figure 13:




Figure 14:




Figure 15:




Figure 16:





Figure 17:

Figure 18: